Drugs / CYNK-001
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04309084 | May 2020 → Jan 2023 | blood coagulation disease, hemorrhagic disease, immunoproliferative disorder, lymphoproliferative syndrome +3 | Celularity Incorporated | Unknown | No outcome recorded |
| Phase 1 | NCT04310592 | Mar 2020 → Jan 2023 | acute myeloid leukemia | Celularity Incorporated | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05218408 | Sep → Oct 2021 | giant cell glioblastoma | Celularity Incorporated | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04365101 | Sep 2020 → Aug 2021 | COVID-19, acute respiratory distress syndrome, immune system disorder, viral pneumonia | Celularity Incorporated | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYNK-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04310592 ↗ |
| Modality | Cell therapy | “cell therapy” NCT04309084 ↗ |
| Route | Intravenous | “Participants received intravenous infusions of CYNK-001 on Days 1, 4, and 7.” NCT04365101 ↗ |